Integrated pathways for neutrophil recruitment and inflammation in leprosy

Journal of Infectious Diseases

Volumn 201, Issue 4, 2010, Pages 558-569

  Lee, Delphine J ^a   Li, Huiying ^a,b,c,d   Ochoa, Maria T ^a   Tanaka, Motoyuki ^h   Carbone, Ryan J ^a   Damoiseaux, Robert ^e   Burdick, Anne ^g   Sarno, Euzenir N ⁱ   Rea, Thomas H ^f   Modlin, Robert L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Molecular and Medical Pharmacology ^*  (Japan)

^e Molecular Screening Shared Resource   (Japan)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h KYOTO UNIVERSITY   (Japan)

ⁱ INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FC RECEPTOR; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; THALIDOMIDE; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL MIGRATION; CELL MOTION; CLINICAL ARTICLE; ENDOTHELIUM CELL; ERYTHEMA NODOSUM LEPROSUM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; LEPROMATOUS LEPROSY; MYCOBACTERIUM LEPRAE; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; PRIORITY JOURNAL; SKIN DEFECT; UPREGULATION;

CLUSTER ANALYSIS; E-SELECTIN; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; LEPROSY; MODELS, BIOLOGICAL; MYCOBACTERIUM LEPRAEMURIUM; NEUTROPHIL INFILTRATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, FC; SIGNAL TRANSDUCTION; SKIN; THALIDOMIDE; TOLL-LIKE RECEPTOR 2;

EID: 75749109372     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650318     Document Type: Article

References (49)

1. Rogers HW, Unanue ER. Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect Immun 1993;61(12): 5090-5096.
2. Miller LS, O'Connell RM, Gutierrez MA, et al. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 2006; 24(1):79-91.
3. Xu Q, Seemanapalli SV, Reif KE, Brown CR, Liang FT. Increasing the recruitment of neutrophils to the site of infection dramatically attenuates Borrelia burgdorferi infectivity. J Immunol 2007; 178(8):5109-5115.
4. Movat HZ. Tissue injury and inflammation induced by immune complexes: the critical role of the neutrophil leukocyte. Exp Mol Pathol 1979; 31(1):201-210.
5. AnthonyJ,VaidyaMC,DasguptaA. Ultrastructureofskininerythemanodosumleprosum.Cytobios1983;36(141):17-23. (Pubitemid13136047)
6. Murphy GF, Sanchez NP, Flynn TC, Sanchez JL, Mihm MC Jr, Soter NA. Erythema nodosum leprosum: nature and extent of the cutaneous microvascular alterations. J Am Acad Dermatol 1986; 14(1):59-69.
7. Waters MF, Rees RJ, Sutherland I. Chemotherapeutic trials in leprosy. V. A study of methods used in clinical trials in lepromatous leprosy. Int J Lepr Other Mycobact Dis 1967; 35(3):311-335.
8. Vengadakrishnan K, Saraswat PK, Mathur PC. A study of rheumatological manifestations of leprosy. Indian J Dermatol Venereol Leprol 2004; 70(2) :76-78.
9. Rea TH, Levan NE. Erythema nodosum leprosum in a general hospital. Arch Dermatol 1975; 111(12):1575-1580.
10. Wemambu SNC, Turk JL, Waters MFR, Rees RJW Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet 1969;2(7627):933-935.
11. Ridley MJ, Ridley DS. The immunopathology of erythema nodosum leprosum: the role of extravascular complexes. Lepr Rev 1983; 54(2): 95-107.
12. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five-group system. Int J Lepr Other Mycobact Dis 1966; 34(3): 255-273.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162(1):156-159. (Pubitemid 17064313)
14. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95(25):14863-14868. (Pubitemid 29003722)
15. Bleharski JR, Li H, Meinken C, et al. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 2003; 301(5639): 1527-1530. (Pubitemid 37128543)
16. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286(5439):531-537.
17. Modlin RL, Hofman FM, Horwitz DA, et al. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. J Immunol 1984; 132(6):3085-3090.
18. TanBH,MeinkenC,BastianM,etal. Macrophagesacquireneutrophilgranulesforantimicrobialactivitya gainstintracellularpathogens.JImmunol2006;177(3):1864-1871.(Pubitemid44092525)
19. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4(5):P3.
20. Mulligan MS, Varani J, Dame MK, et al. Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest 1991;88(4):1396-1406.
21. Lawrence MB, Springer TA. Neutrophils roll on E-selectin. J Immunol 1993;151(11):6338-6346.
22. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-306.
23. SampaioEP,KaplanG,MirandaA,etal. Theinfluenceofthalidomideontheclinicalandimmunologicmanifestationoferythem anodosumleprosum.JInfectDis1993;168(2):408-414.(Pubitemid23210619)
24. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993; 177(6):1675-1680.
25. Rodrigues GB, Passos GF, Di GG, et al. Preventive and therapeutic antiinflammatory effects of systemic and topical thalidomide on endotoxininduced uveitis in rats. Exp Eye Res 2007;84(3):553-560.
26. van CR, Vonk AG, Netea MG, Kullberg BJ, van der Meer JW Modulation of LPS-, PHA- and M. tuberculosis-mediated cytokine production by pentoxifylline and thalidomide. Eur Cytokine Netw 2000; 11(4): 574-579.
27. Wnendt S, Finkam M, Winter W, Ossig J, Raabe G, Zwingenberger K. Enantioselective inhibition of TNF-a release by thalidomide and thalidomide-analogues. Chirality 1996;8(5):390-396. (Pubitemid 26363811)
28. Krutzik SR, Ochoa MT, Sieling PA, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 2003; 9(5): 525-532. (Pubitemid 36597097)
29. Oliveira RB, Moraes MO, Oliveira EB, Sarno EN, Nery JA, Sampaio EP. Neutrophils isolated from leprosy patients release TNF-α and exhibit accelerated apoptosis in vitro. J Leukoc Biol 1999;65(3):364-371.
30. Raab M, Daxecker H, Markovic S, Karimi A, Griesmacher A, Mueller MM. Variation of adhesion molecule expression on human umbilical vein endothelial cells upon multiple cytokine application. Clin Chim Acta 2002; 321(1-2):11-16. (Pubitemid 34597046)
31. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin-1 activation of vascular endothelium: effects on procoagulant activity and leukocyte adhesion. Am J Pathol 1985; 121(3):394-403.
32. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985;76(5):2003-2011.
33. Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G. Prolonged treatment with recombinant interferon γ induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175(6):1729-11237
34. MulliganMS,WatsonSR,FennieC,WardPA. Protectiveeffectsofselectinchimerasinneutrophil-mediatedlunginjury. JImmunol1993;151(11):6410-6417.(Pubitemid23340387)
35. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 1969; 37(2):135-146.
36. Eski M, Sahin I, Sengezer M, Serdar M, Ifran A. Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: is it a new drug for modulation of systemic inflammatory response. Burns 2008; 34(1):104-108.
37. Malleo G, Mazzon E, Genovese T, et al. Effects of thalidomide in a mouse model of cerulein-induced acute pancreatitis. Shock 2008; 29(1): 89-97.
38. Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol 2005;52(3):500-508.
39. HamuryudanV,MatC,SaipS,etal. ThalidomideinthetreatmentofthemucocutaneouslesionsoftheBehcetsyndrome: arandomized,double-blind,placebo-controlledtrial.AnnInternMed1998;128(6): 443-450.(Pubitemid28128704)
40. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the antiinflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984; 11(5):814-819.
41. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes Chemotaxis by thalidomide. Arch Dermatol Res 1980;269(3):275-280. (Pubitemid 11207096)
42. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31(2-3):213-221. (Pubitemid 26122649)
43. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173(3):699-703.
44. Shannon E, Noveck R, Sandoval F, Kamath B. Thalidomide suppressed IL-1β while enhancing TNF-a and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol 2008; 30(3) :447-457.
45. BurneMJ,RabbH. Pathophysiologicalcontributionsoffucosyltransferasesinrenalischemiareperfu sioninjury.JImmunol2002;169(5):2648-2652.(Pubitemid34921012)
46. Asano M, Nakae S, Kotani N, et al. Impaired selectin-ligand biosynthesis and reduced inflammatory responses in β-1,4-galactosyltransferase-I- deficient mice. Blood 2003; 102(5):1678-1685. (Pubitemid 37022560)
47. Shoda H, Inokuma S, Yajima N, Tanaka Y, Setoguchi K. Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment. Ann Rheum Dis 2005; 64(4) :651-652. (Pubitemid 40469106)
48. Mindrescu C, Le J, Wisniewski HG, Vilcek J. Up-regulation of cyclooxygenase-2 expression by TSG-6 protein in macrophage cell line. Biochem Biophys Res Commun 2005;330(3):737-745. (Pubitemid 40462149)
49. Rogers HW, Tripp CS, Schreiber RD, Unanue ER. Endogenous IL-1 is required for neutrophil recruitment and macrophage activation during murine listeriosis. J Immunol 1994; 153(5):2093-2101.